28 February 2019

André van der Ven and Mihai Netea, theme Infectious diseases and global health, and colleagues, will receive 15 million Euro from pharmaceutical company ViiV Healthcare for research into new ways to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV.

Collaboration will process anonymised patient data, genetic information and environmental factors in order to understand the biology associated with HIV better and identify targets for new medicines earlier. 

ViiV Healthcare is announcing a five-year collaboration with researchers of the Radboudumc, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). The HFGP is a large-scale project that combines detailed patient data with cross-omics information, host immune responses and environmental factors to better understand how the body recognizes and defends itself from disease as well as the signs, symptoms and progression of disease.

Under the supervision of a Scientific Management Board (SMB) comprising representatives from Radboudumc and ViiV Healthcare, Radboudumc will expand the cohort of HIV-infected individuals that are part of the HFGP from 200 to 2000 people. Data from this cohort will be used to look at the predictors and pathways of diseases that are specific to people living with HIV and how they might differ from other disease areas and from healthy people who do not have HIV. Using that information, the goal is to identify early stage drug targets that ViiV Healthcare could use to develop new medicines or approaches to treat HIV infection.

The project, called 'HIV 2000+' will be the first comprehensive cohort study in HIV to use a field of biology called 'cross-omics,' which uses genomics, microbiome metagenomics and metabolomics technologies to better understand the underlying biology associated with HIV infection.

Jan van Lunzen, MD PhD, Head of Translational Medical Research at ViiV Healthcare and project coordinator said: “This project will enable us to establish one of the best characterized cohorts of people living with HIV in the world and will not only help to better define biomarkers and pathways of disease progression, but may also serve as a fantastic platform to find new drug targets.”
 
The collaboration will combine Radboudumc’s experience in infectious diseases, established networks and scientific techniques with ViiV Healthcare’s expertise and innovation in discovering and developing medicines for HIV.

Mihai Netea said: “This is a unique, first-time collaboration which will combine in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV. It is a unique chance to understand the HIV infection and its complications better, and to partner with ViiV Healthcare to translate that knowledge to the bed of the patient.”

Deal terms

ViiV Healthcare will fully fund the five-year collaboration that will analyze cross-omics data from 2,000 HIV-infected patients and compare this data to that from other disease-areas and to data from healthy volunteers.  Scientists from both Radboudumc and ViiV Healthcare will collaborate closely on the work packages that will be formed as part of the collaboration.

A SMB, comprising members from both Radboudumc and ViiV Healthcare, will provide both scientific and financial oversight of the collaboration. An Independent Scientific Advisory Board will be formed to advise the SMB.

Related news items


Step-up approach vs open necrosectomy for necrotizing pancreatitis

18 April 2019

Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.

read more

Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients

18 April 2019

In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.

read more

Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?

18 April 2019

In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.

read more

ESCMID award for groundbreaking studies on NTM disease

18 April 2019

Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.

read more

Honorary Membership Japanese Radiological Society

18 April 2019

During the annual meeting of the Japanese Radiological Society in Yokohama Jelle Barentsz became honorary member.

read more

EU funded project BIOMAP led by Ellen van den Bogaard

12 April 2019

Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.

read more